Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Google Secures Pentagon AI Deal for Classified Projects 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
HEIDELBERG, Germany, Feb. 22, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that its CMO, Jens-Peter Marschner, will present at the symposium titled "Emerging Approaches in Cancer Immunotherapy" in New York City on Monday, February 29 at 12:10-12:40 pm Eastern Standard Time. The symposium will be presented as part of the New York Academy of Sciences' Cancer and Signaling Discussion Group, which provides a forum for scientists from academia, industry, and government, as well as other stakeholders, to come together to explore cutting-edge topics in the field. A live webcast of Affimed's presentation will be available through the New York Academy of Sciences' website at www.nyas.org.
About Affimed N.V.
Affimed (Nasdaq:AFMD) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called natural killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head of IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
